nach oben

Erschienen in:

01.02.2012 | Original article

Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging

verfasst von: Keigo Shimoji, Shigeki Aoki, Atsushi Nakanishi, Michimasa Suzuki, Masaaki Hori, Syuji Sato, Haruyoshi Hoshito, Shinsuke Kyogoku, Narisumi Cho, Yutaka Ozaki, Masaru Suzuki, Ryohei Kuwatsuru, Keisuke Sasai

Erschienen in: Japanese Journal of Radiology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to elucidate the distribution of estimated glomerular filtration rate (eGFR) values in patients who underwent gadolinium-based contrast agent (GBCA)-enhanced magnetic resonance imaging (MRI) at different types of hospitals.

Materials and methods

We retrospectively studied 2,550 patients who underwent MRI at five institutions. We recorded the date and value of each patient’s eGFR test. The distribution of eGFR values was compared with that in the general Japanese population.

Results

A total of 84.3% of patients had their eGFRs evaluated before GBCA-enhanced MRI. Of these, 84.7% were evaluated within 3 months before the GBCA-enhanced MRI, and 1.3% were evaluated on the day of the GBCA-enhanced MRI. A total of 87.2% of patients tested had an eGFR of ≥60 ml/min/1.73 m²; 12.8% had an eGFR of <60 and ≥30 ml/min/1.73 m², and no patients had an eGFR of <30 ml/min/1.73 m².

Conclusion

The rate of renal function evaluation differed among hospitals. The prevalence of low eGFR values was greater in Juntendo Tokyo Koto Geriatric Medical Center than in the other hospitals, and the prevalence of low eGFR values was greater in patients who underwent GBCA-enhanced MRI than in the general Japanese population.

Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000–1.PubMedCrossRef

Tamura S, Sugimoto H, Tsushima Y, Hayashi H, Fukuda K, Korogi Y, et al. Guidelines for administering gadolinium based contrast agents to patients with renal dysfunction. Japanese Radiological Society. 2008. http://www.radiology.jp/uploads/photos/743.pdf

Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol. 2010;83(991):590–5.PubMedCrossRef

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.PubMedCrossRef

Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11(2):156–63.PubMedCrossRef

Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011;260(1):105–11.PubMedCrossRef

Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol. 2008;66(2):180–3.PubMedCrossRef

Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases. Radiology. 2009;250(2):371–7.PubMedCrossRef

Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology. 2010;256:735–43.PubMedCrossRef

10.

Thomsen HS. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin N Am. 2009;47:871–5.PubMedCrossRef

11.

Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin N Am. 2009;47:833–40.PubMedCrossRef

12.

Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol. 2009;53:1621–8.PubMedCrossRef

13.

Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129–39.PubMedCrossRef

14.

Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol. 2008;180:830–5.PubMedCrossRef

15.

Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807–16.PubMedCrossRef

16.

Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148–57.PubMedCrossRef

Titel: Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging
verfasst von: Keigo Shimoji
Shigeki Aoki
Atsushi Nakanishi
Michimasa Suzuki
Masaaki Hori
Syuji Sato
Haruyoshi Hoshito
Shinsuke Kyogoku
Narisumi Cho
Yutaka Ozaki
Masaru Suzuki
Ryohei Kuwatsuru
Keisuke Sasai
Publikationsdatum: 01.02.2012
Verlag: Springer Japan
Erschienen in: Japanese Journal of Radiology / Ausgabe 2/2012
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-011-0019-6

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging